Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of Subretinal AAV Gene Therapies in Choroideremia
2017-003104-42Phase 3Active
- Sponsor
- Nightstar Therapeutics
- Start
- Sep 2017
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of timrepigene emparvovec in choroideremia (2 arms), sponsored by Nightstar Therapeutics. Primary endpoint: Safety of AAV2-REP1 and AAV8-RPGR. Started Sep 2017; status: active.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on 2017-003104-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003104-42.